Home/Pipeline/Chidamide (Tucidinostat)

Chidamide (Tucidinostat)

Lymphoma (and other cancers)

Approved/MarketedCommercial; Included in NRDL

Key Facts

Indication
Lymphoma (and other cancers)
Phase
Approved/Marketed
Status
Commercial; Included in NRDL
Company

About Chipscreen Biosciences

A Chinese biotech pioneer developing original small molecule drugs for oncology and metabolic diseases using chemical genomics and AI platforms.

View full company profile